**LUNG DISEASE SITE AGENDA**

**NCIC CLINICAL TRIALS GROUP**

**LUNG**

**DISEASE SITE COMMITTEE MEETING AGENDA**

**DELTA CHELSEA HOTEL, TORONTO**

**ROOM: CHURCHILL A**

**SATURDAY APRIL 27th, 2013**

1:30 – 4:15 PM, EST

**CHAIRS: G. GOSS / Y. UNG**

---

**Objectives:**

To summarize recent developments in the understanding of molecular biology and therapeutics as these relate to the management of lung cancer.

To cite and analyze recent results of lung cancer clinical studies conducted by or in collaboration with NCIC Clinical Trials Group.

---

1:30 – 1:40 pm  
**Welcome and Review of the year**  
G. Goss/Y. Ung

1:40 – 2:30 pm  
**Report from Study Chairs: Update on Current Trials**

**BR.26:**

A Double Blind Placebo Controlled Randomized Trial Of PF-804 In Patients With Incurable Stage IIIB/IV Non-Small Cell Lung Cancer After Failure Of Standard Therapy For Advanced Or Metastatic Disease  

P. Ellis

**BRC.2/BRC.2E:**

A Phase III Randomized Trial Of Adjuvant Chemotherapy With Or Without Bevacizumab For Patients With Completely Resected Stage IB (> 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC) / A Prospective Economic Analysis Of NCIC CTG BRC.2/E1505  

C. Butts

**BRC.5:**

A Phase III Randomized Trial Of Lobectomy Versus Sublobar Resection For Small (< 2cm) Peripheral Non-Small Cell Lung Cancer  

J. Deslauriers

**BR.28:**

Concurrent Once-Daily Versus Twice-Daily Radiotherapy: A 2-Arm Randomised Controlled Trial Of Concurrent Chemo-Radiotherapy Comparing Twice-Daily And Once-Daily Radiotherapy Schedules In Patients With Limited Stage Small Cell Lung Cancer (SCLC) And Good Performance Status  

A. Bezjak
IND.207:  
A Phase II Study Of PF-03446962 In Patients With Advanced Malignant Pleural Mesothelioma  
Q. Chu

IND.211:  
A Randomized Phase II Study Of Reolysin In Patients With Previously Treated Advanced Or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy  
D. Morris

IND.215:  
A Phase Ib Study Of Selumetinib In Patients With Previously Treated Or Untreated Advanced/Metastatic Nsclc Who Are Receiving Standard Chemotherapy Regimen  
G. Nicholas

2:30 – 2:40 pm   BREAK

2:40 – 4:00 pm   New Concepts and Proposals  
• NSCLC  
• Small cell lung cancer  
G. Goss/Y. Ung

4.00 – 4:15 pm   Summary and Close  
G. Goss/Y. Ung